Dopamine Therapy Fails to Address Reward Sensitivity Deficits in PD Depression
Overview
This study demonstrates that depression in Parkinson’s disease (PD) is characterized by reduced reward sensitivity during effort-based decision making. While dopaminergic medication improves reward sensitivity in non-depressed PD patients, it does not restore this function in PD patients with depression, indicating a dopamine-unresponsive mechanism underlying motivational deficits.
Background
Depression affects up to one-third of individuals with Parkinson’s disease and is associated with significant disability and poor quality of life. Motivational symptoms such as apathy and anhedonia are prominent in PD depression and are linked to dopaminergic loss in the mesolimbic system. Effort-based decision making, which involves evaluating reward against effort costs, is a key neurocognitive process modulated by dopamine and implicated in motivation. Understanding how dopamine influences this process in PD depression is critical for developing effective treatments.
Data Highlights
Group
Number of Participants
Task Sessions
Medication State
PD with Depression
62
2 (ON and OFF medication)
ON and OFF dopaminergic medication
PD without Depression
62
2 (ON and OFF medication)
ON and OFF dopaminergic medication
Depression without PD
34
1
Not applicable
Healthy Controls
29
1
Not applicable
Key Findings
PD patients with depression showed significantly lower acceptance of effort-reward offers compared to non-depressed PD patients, depressed non-PD patients, and healthy controls.
The reduced acceptance was driven by markedly lower reward sensitivity rather than increased effort sensitivity.
Dopaminergic medication improved reward sensitivity in non-depressed PD patients but failed to do so in PD patients with depression.
Effort sensitivity did not significantly differ between depressed and non-depressed PD patients or change with dopaminergic medication.
These results suggest that motivational deficits in PD depression are linked to disrupted reward processing that is unresponsive to dopamine therapy.
Clinical Implications
Clinicians should recognize that dopaminergic therapies may not adequately address motivational symptoms such as apathy and anhedonia in PD patients with depression. Alternative or adjunctive treatments targeting non-dopaminergic pathways involved in reward sensitivity may be necessary. Assessment of effort-based decision making could help identify patients who might benefit from such tailored interventions.
Conclusion
Disrupted reward sensitivity underlies motivational deficits in PD depression and is not improved by dopaminergic medication. This highlights the need for novel therapeutic strategies beyond dopamine replacement to effectively treat depression in Parkinson’s disease.
